Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial-Reference-Cited by-同舟云学术

Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial

Published:2004-02-02 Issue:3 Volume:60 Page:197-204
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Burch Patrick A.,Croghan Gary A.,Gastineau Dennis A.,Jones Lori A.,Kaur Judith S.,Kylstra Jelle W.,Richardson Ronald L.,Valone Frank H.,Vuk-Pavlović Stanimir

Publisher

Wiley

Subject

Urology,Oncology

Reference23 articles.

1. Cancer statistics;Jemal;CA Cancer J Clin,2002

2. Systemic treatment for prostate cancer;Dowling;Cancer Treat Rev,1998

3. Clinical trials in relapsed prostate cancer: Defining the target;Scher;J Natl Cancer Inst,1996

4. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm;Small;J Clin Oncol,1997

5. Management of hormone refractory prostate cancer: Current standards and future prospects;Oh;J Urol,1998

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osteoimmunology in bone malignancies: A symphony with evil;Journal of the National Cancer Center;2024-09

2. Vaccines as treatments for prostate cancer;Nature Reviews Urology;2023-03-06

3. Stationary distribution and persistence of a stochastic mathematical model for prostate cancer with pulsed therapy;Applied Mathematical Modelling;2023-02

4. Immunotherapy;Medicines for Cancer;2023

5. Development and application of bionic systems consisting of tumor-cell membranes;Journal of Zhejiang University-SCIENCE B;2022-09